건선 환자에서 adalimumab 치료 중 발생한 B형 간염의 재활성화 = Hepatitis B reactivation During Adalimumab Treatment in a Patient with Psoriasis

다국어 초록 (Multilingual Abstract)

Adalimumab, tumor necrosis factor-alpha inhibitor, has been used for the treatment of various immune-mediated inflammatory diseases including psoriasis. However, it may cause hepatitis B virus (HBV) reactivation. A 64 years-old male patient presented with plaque psoriasis for 15 years’ duration. After receiving phototherapy and oral methotrexate for 6 months, adalimumab treatment was started due to inefficacy. He has been regularly follow-up at the local clinic as a chronic HBV carrier. Before adalimumab treatment, HBV DNA level was 1.15×102 IU/ml. However, the level gradually increased to 2.07×104 IU/ml at 6 months and 2.02×105 IU/ml at 12 months of treatment. Adalimumab was discontinued and he was referred to a hepatologist. He was identified as an HBV inactive carrier, and has been observed with 6-month follow-up. This case report highlights the importance of screening and preventing HBV reactivation in patients using immunosuppressive drugs.

참고문헌 (Reference)

1 Norah A, "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance" 67 : 1560-1599, 2018

2 임선영, "The epidemiology of hepatitis B virus infection in Korea" 대한내과학회 34 (34): 945-953, 2019

3 Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA" 343 : 1221-1228, 2014

4 Caporali R, "Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers(hepatitis B surface antigen negative/anti-hepatitis B core antigen positive)with rheumatic diseases" 62 : 749-754, 2010

5 Ramiro S, "Safety of synthetic and biological DMARDs : a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis" 73 : 529-535, 2014

6 J Sanz-Bueno, "Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20cases from the BIOBADADERM database" 106 : 477-482, 2015

7 J Sanz-Bueno, "Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics : a retrospective analysis of 20cases from the BIOBADADERM database" 106 : 477-482, 2015

8 Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B" 대한간학회 25 (25): 93-159, 2019

9 Arora A, "INASL Guidelines on management of hepatitis B vrus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids" 8 : 403-431, 2018

10 Cannizzaro MV, "Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management" 7 : 35-40, 2017

11 Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions" 152 : 1297-1309, 2017

12 G Lapadula, "Adalimumab in the treatment of immune-mediated diseases" 27 : 33-48, 2014